Myeloma highlights at EHA 2017

The most important Haematology scientific meeting in Europe, the European Hematology Association (EHA) Annual Meeting was held between 22 and 25 June 2017 in Madrid (Spain).
The impact of cytogenetic analysis in myeloma as an important genetic risk factor, updated results on the Pollux and Castor prospective clinical trials including daratumumab in triplet combination of drugs and the possibility to combine not only three drugs but four drugs in myeloma frontline treatment setting, were some of the topic discussed reagarding myeloma.
Dr Anna Sureda, Head of Hematology Department, Institut CatalĂ  d’OncologĂ­a (ICO), Spain, explains the most important myeloma highlights presented during this congress.